<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Endemic Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) is considered to preferentially develop in equatorial Africa because of <z:hpo ids='HP_0011010'>chronic</z:hpo> co-<z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> with Epstein-Barr virus (EBV) and the <z:e sem="disease" ids="C0024530" disease_type="Disease or Syndrome" abbrv="">malaria</z:e> pathogen Plasmodium falciparum </plain></SENT>
<SENT sid="1" pm="."><plain>The interaction and contribution of both pathogens in the oncogenic process are poorly understood </plain></SENT>
<SENT sid="2" pm="."><plain>Earlier, we showed that immune activation with a synthetic Toll-like receptor 9 (TLR9) ligand suppresses the initiation of EBV lytic replication in primary human B cells </plain></SENT>
<SENT sid="3" pm="."><plain>In this study we investigate the mechanism involved in the suppression of EBV lytic gene expression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines </plain></SENT>
<SENT sid="4" pm="."><plain>We show that this suppression is dependent on functional TLR9 and MyD88 signaling but independent of downstream signaling elements, including phosphatidylinositol-3 kinase, <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinases and nuclear factor-kappaB </plain></SENT>
<SENT sid="5" pm="."><plain>We identified TLR9 triggering resulting in <z:chebi fb="0" ids="15358">histone</z:chebi> modifications to negatively affect the activation of the promoter of EBV's master regulatory lytic gene BZLF1 </plain></SENT>
<SENT sid="6" pm="."><plain>Finally, we show that P. falciparum hemozoin, a natural TLR9 ligand, suppresses induction of EBV lytic gene expression in a dose-dependent manner </plain></SENT>
<SENT sid="7" pm="."><plain>Thus, we provide evidence for a possible interaction between P. falciparum and EBV at the B-cell level and the mechanism involved in suppressing lytic and thereby reinforcing latent EBV that has unique oncogenic potential </plain></SENT>
</text></document>